Shanghai Pharmaceuticals Holding (02607) reported a first-quarter net profit attributable to the parent company of 1.418 billion yuan, an increase of 6.35% year-on-year.
Shanghai Pharmaceuticals (02607) released its first quarter report for 2026, with a revenue of 75.262 billion yuan, a year-on-year increase of 6.36%. The net profit attributable to the shareholders of the listed company was 1.418 billion yuan, a year-on-year increase of 6.35%. The basic earnings per share were 0.3823 yuan.
Shanghai Pharmaceuticals Holding (02607) released its first quarter report for 2026, with operating income of 75.262 billion yuan (RMB, same below), a year-on-year increase of 6.36%. Net profit attributable to shareholders of the listed company was 1.418 billion yuan, a year-on-year increase of 6.35%. Basic earnings per share were 0.3823 yuan.
Related Articles
SIICENVIRONMENT (00807) will distribute a final dividend of SGD 0.011 per share on May 29th.
Fudan Zhangjiang (01349) announces its first-quarter financial performance with a net profit attributed to the parent company of approximately 7.71 million yuan, an increase of 189.36% year-on-year.
On April 29, HENGAN INT'L (01044) spent 8.668 million Hong Kong dollars to repurchase 320,000 shares.
SIICENVIRONMENT (00807) will distribute a final dividend of SGD 0.011 per share on May 29th.
Fudan Zhangjiang (01349) announces its first-quarter financial performance with a net profit attributed to the parent company of approximately 7.71 million yuan, an increase of 189.36% year-on-year.
On April 29, HENGAN INT'L (01044) spent 8.668 million Hong Kong dollars to repurchase 320,000 shares.
RECOMMEND
